{"pmid":32350462,"title":"Antibody responses to SARS-CoV-2 in patients with COVID-19.","text":["Antibody responses to SARS-CoV-2 in patients with COVID-19.","We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections.","Nat Med","Long, Quan-Xin","Liu, Bai-Zhong","Deng, Hai-Jun","Wu, Gui-Cheng","Deng, Kun","Chen, Yao-Kai","Liao, Pu","Qiu, Jing-Fu","Lin, Yong","Cai, Xue-Fei","Wang, De-Qiang","Hu, Yuan","Ren, Ji-Hua","Tang, Ni","Xu, Yin-Yin","Yu, Li-Hua","Mo, Zhan","Gong, Fang","Zhang, Xiao-Li","Tian, Wen-Guang","Hu, Li","Zhang, Xian-Xiang","Xiang, Jiang-Lin","Du, Hong-Xin","Liu, Hua-Wen","Lang, Chun-Hui","Luo, Xiao-He","Wu, Shao-Bo","Cui, Xiao-Ping","Zhou, Zheng","Zhu, Man-Man","Wang, Jing","Xue, Cheng-Jun","Li, Xiao-Feng","Wang, Li","Li, Zhi-Jie","Wang, Kun","Niu, Chang-Chun","Yang, Qing-Jun","Tang, Xiao-Jun","Zhang, Yong","Liu, Xia-Mao","Li, Jin-Jing","Zhang, De-Chun","Zhang, Fan","Liu, Ping","Yuan, Jun","Li, Qin","Hu, Jie-Li","Chen, Juan","Huang, Ai-Long","32350462"],"abstract":["We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections."],"journal":"Nat Med","authors":["Long, Quan-Xin","Liu, Bai-Zhong","Deng, Hai-Jun","Wu, Gui-Cheng","Deng, Kun","Chen, Yao-Kai","Liao, Pu","Qiu, Jing-Fu","Lin, Yong","Cai, Xue-Fei","Wang, De-Qiang","Hu, Yuan","Ren, Ji-Hua","Tang, Ni","Xu, Yin-Yin","Yu, Li-Hua","Mo, Zhan","Gong, Fang","Zhang, Xiao-Li","Tian, Wen-Guang","Hu, Li","Zhang, Xian-Xiang","Xiang, Jiang-Lin","Du, Hong-Xin","Liu, Hua-Wen","Lang, Chun-Hui","Luo, Xiao-He","Wu, Shao-Bo","Cui, Xiao-Ping","Zhou, Zheng","Zhu, Man-Man","Wang, Jing","Xue, Cheng-Jun","Li, Xiao-Feng","Wang, Li","Li, Zhi-Jie","Wang, Kun","Niu, Chang-Chun","Yang, Qing-Jun","Tang, Xiao-Jun","Zhang, Yong","Liu, Xia-Mao","Li, Jin-Jing","Zhang, De-Chun","Zhang, Fan","Liu, Ping","Yuan, Jun","Li, Qin","Hu, Jie-Li","Chen, Juan","Huang, Ai-Long"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350462","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41591-020-0897-1","topics":["Diagnosis"],"weight":1,"_version_":1666138495590072322,"score":9.490897,"similar":[{"pmid":32221519,"pmcid":"PMC7184337","title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.","text":["Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.","BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.","Clin Infect Dis","Zhao, Juanjuan","Yuan, Quan","Wang, Haiyan","Liu, Wei","Liao, Xuejiao","Su, Yingying","Wang, Xin","Yuan, Jing","Li, Tingdong","Li, Jinxiu","Qian, Shen","Hong, Congming","Wang, Fuxiang","Liu, Yingxia","Wang, Zhaoqin","He, Qing","Li, Zhiyong","He, Bin","Zhang, Tianying","Fu, Yang","Ge, Shengxiang","Liu, Lei","Zhang, Jun","Xia, Ningshao","Zhang, Zheng","32221519"],"abstract":["BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients."],"journal":"Clin Infect Dis","authors":["Zhao, Juanjuan","Yuan, Quan","Wang, Haiyan","Liu, Wei","Liao, Xuejiao","Su, Yingying","Wang, Xin","Yuan, Jing","Li, Tingdong","Li, Jinxiu","Qian, Shen","Hong, Congming","Wang, Fuxiang","Liu, Yingxia","Wang, Zhaoqin","He, Qing","Li, Zhiyong","He, Bin","Zhang, Tianying","Fu, Yang","Ge, Shengxiang","Liu, Lei","Zhang, Jun","Xia, Ningshao","Zhang, Zheng"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221519","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1093/cid/ciaa344","keywords":["covid-19","sars-cov-2","antibody"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1666138490458341376,"score":346.77914},{"pmid":32428207,"title":"Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.","text":["Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.","BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel beta-coronavirus that has recently emerged as the cause of the 2019 coronavirus pandemic (COVID-19). Polymerase chain reaction (PCR) based tests are optimal and recommended for the diagnosis of an acute SARS-CoV-2 infection. Serology tests for viral antibodies provide an important tool to diagnose previous exposure to the virus. Here we evaluate the analytical performance parameters of the Diazyme SARS-CoV-2 IgM/IgG serology assays and describe the kinetics of IgM and IgG seroconversion observed in patients with PCR confirmed COVID-19 who were admitted to our hospital. METHODS: We validated the performance of the Diazyme assay in 235 subjects to determine specificity. Subsequently, we evaluated the SARS-CoV-2 IgM and IgG seroconversion of 54 PCR confirmed COVID-19 patients and determined sensitivity of the assay at three different timeframes. RESULT: Sensitivity and specificity for detecting seropositivity at >/= 15 days following a positive SARS-CoV-2 PCR result, was 100.0% and 98.7% when assaying for the panel of IgM and IgG. The median time to seropositivity observed for a reactive IgM and IgG result from the date of a positive PCR was 5 days (IQR: 2.75-9 days) and 4 days (IQR: 2.75-6.75 days), respectively. CONCLUSIONS: Our data demonstrates that the Diazyme IgM/IgG assays are suited for the purpose of detecting SARS-CoV-2 IgG and IgM in patients with suspected SARS-CoV-2 infections. For the first time, we report longitudinal data showing the evolution of seroconversion for both IgG and IgM in a cohort of acutely ill patients in the United States. We also demonstrate a low false positive rate in patients who were presumed to be disease free.","J Appl Lab Med","Suhandynata, Raymond T","Hoffman, Melissa A","Kelner, Michael J","McLawhon, Ronald W","Reed, Sharon L","Fitzgerald, Robert L","32428207"],"abstract":["BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel beta-coronavirus that has recently emerged as the cause of the 2019 coronavirus pandemic (COVID-19). Polymerase chain reaction (PCR) based tests are optimal and recommended for the diagnosis of an acute SARS-CoV-2 infection. Serology tests for viral antibodies provide an important tool to diagnose previous exposure to the virus. Here we evaluate the analytical performance parameters of the Diazyme SARS-CoV-2 IgM/IgG serology assays and describe the kinetics of IgM and IgG seroconversion observed in patients with PCR confirmed COVID-19 who were admitted to our hospital. METHODS: We validated the performance of the Diazyme assay in 235 subjects to determine specificity. Subsequently, we evaluated the SARS-CoV-2 IgM and IgG seroconversion of 54 PCR confirmed COVID-19 patients and determined sensitivity of the assay at three different timeframes. RESULT: Sensitivity and specificity for detecting seropositivity at >/= 15 days following a positive SARS-CoV-2 PCR result, was 100.0% and 98.7% when assaying for the panel of IgM and IgG. The median time to seropositivity observed for a reactive IgM and IgG result from the date of a positive PCR was 5 days (IQR: 2.75-9 days) and 4 days (IQR: 2.75-6.75 days), respectively. CONCLUSIONS: Our data demonstrates that the Diazyme IgM/IgG assays are suited for the purpose of detecting SARS-CoV-2 IgG and IgM in patients with suspected SARS-CoV-2 infections. For the first time, we report longitudinal data showing the evolution of seroconversion for both IgG and IgM in a cohort of acutely ill patients in the United States. We also demonstrate a low false positive rate in patients who were presumed to be disease free."],"journal":"J Appl Lab Med","authors":["Suhandynata, Raymond T","Hoffman, Melissa A","Kelner, Michael J","McLawhon, Ronald W","Reed, Sharon L","Fitzgerald, Robert L"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428207","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/jalm/jfaa079","keywords":["covid-19","sars-cov-2","antibody","diagnosis","serology"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1667352728708317184,"score":340.68613},{"pmid":32430429,"title":"Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset.","text":["Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset.","BACKGROUND: Timely diagnosis of SARS-CoV-2 infection is a prerequisite for treatment and prevention. The serology characteristics and complement diagnosis value of the antibody test to RNA test need to be demonstrated. METHOD: Serial sera of 80 patients with PCR-confirmed COVID-19 were collected at the First Affiliated Hospital of Zhejiang University, China. Total antibody (Ab), IgM and IgG antibodies against SARS-CoV-2 were detected, and the antibody dynamics during the infection were described. RESULTS: The seroconversion rates for Ab, IgM and IgG were 98.8%, 93.8% and 93.8%, respectively. The first detectible serology marker was Ab, followed by IgM and IgG, with a median seroconversion time of 15, 18 and 20 days post exposure (d.p.e) or 9, 10 and 12 days post onset (d.p.o), respectively. The antibody levels increased rapidly beginning at 6 d.p.o. and were accompanied by a decline in viral load. For patients in the early stage of illness (0-7 d.p.o), Ab showed the highest sensitivity (64.1%) compared to IgM and IgG (33.3% for both, p<0.001). The sensitivities of Ab, IgM and IgG increased to 100%, 96.7% and 93.3% 2 weeks later, respectively. When the same antibody type was detected, no significant difference was observed between enzyme-linked immunosorbent assays and other forms of immunoassays. CONCLUSIONS: A typical acute antibody response is induced during SARS-CoV-2 infection. Serology testing provides an important complement to RNA testing in the later stages of illness for pathogenic specific diagnosis and helpful information to evaluate the adapted immunity status of patients.","Eur Respir J","Lou, Bin","Li, Ting-Dong","Zheng, Shu-Fa","Su, Ying-Ying","Li, Zhi-Yong","Liu, Wei","Yu, Fei","Ge, Sheng-Xiang","Zou, Qian-Da","Yuan, Quan","Lin, Sha","Hong, Cong-Ming","Yao, Xiang-Yang","Zhang, Xue-Jie","Wu, Ding-Hui","Zhou, Guo-Liang","Hou, Wang-Heng","Li, Ting-Ting","Zhang, Ya-Li","Zhang, Shi-Yin","Fan, Jian","Zhang, Jun","Xia, Ning-Shao","Chen, Yu","32430429"],"abstract":["BACKGROUND: Timely diagnosis of SARS-CoV-2 infection is a prerequisite for treatment and prevention. The serology characteristics and complement diagnosis value of the antibody test to RNA test need to be demonstrated. METHOD: Serial sera of 80 patients with PCR-confirmed COVID-19 were collected at the First Affiliated Hospital of Zhejiang University, China. Total antibody (Ab), IgM and IgG antibodies against SARS-CoV-2 were detected, and the antibody dynamics during the infection were described. RESULTS: The seroconversion rates for Ab, IgM and IgG were 98.8%, 93.8% and 93.8%, respectively. The first detectible serology marker was Ab, followed by IgM and IgG, with a median seroconversion time of 15, 18 and 20 days post exposure (d.p.e) or 9, 10 and 12 days post onset (d.p.o), respectively. The antibody levels increased rapidly beginning at 6 d.p.o. and were accompanied by a decline in viral load. For patients in the early stage of illness (0-7 d.p.o), Ab showed the highest sensitivity (64.1%) compared to IgM and IgG (33.3% for both, p<0.001). The sensitivities of Ab, IgM and IgG increased to 100%, 96.7% and 93.3% 2 weeks later, respectively. When the same antibody type was detected, no significant difference was observed between enzyme-linked immunosorbent assays and other forms of immunoassays. CONCLUSIONS: A typical acute antibody response is induced during SARS-CoV-2 infection. Serology testing provides an important complement to RNA testing in the later stages of illness for pathogenic specific diagnosis and helpful information to evaluate the adapted immunity status of patients."],"journal":"Eur Respir J","authors":["Lou, Bin","Li, Ting-Dong","Zheng, Shu-Fa","Su, Ying-Ying","Li, Zhi-Yong","Liu, Wei","Yu, Fei","Ge, Sheng-Xiang","Zou, Qian-Da","Yuan, Quan","Lin, Sha","Hong, Cong-Ming","Yao, Xiang-Yang","Zhang, Xue-Jie","Wu, Ding-Hui","Zhou, Guo-Liang","Hou, Wang-Heng","Li, Ting-Ting","Zhang, Ya-Li","Zhang, Shi-Yin","Fan, Jian","Zhang, Jun","Xia, Ning-Shao","Chen, Yu"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430429","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1183/13993003.00763-2020","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1667342288297132032,"score":333.57922},{"pmid":32306047,"pmcid":"PMC7188146","title":"Antibody Detection and Dynamic Characteristics in Patients with COVID-19.","text":["Antibody Detection and Dynamic Characteristics in Patients with COVID-19.","BACKGROUND: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. METHODS: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. RESULTS: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. CONCLUSIONS: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.","Clin Infect Dis","Xiang, Fei","Wang, Xiaorong","He, Xinliang","Peng, Zhenghong","Yang, Bohan","Zhang, Jianchu","Zhou, Qiong","Ye, Hong","Ma, Yanling","Li, Hui","Wei, Xiaoshan","Cai, Pengcheng","Ma, Wan-Li","32306047"],"abstract":["BACKGROUND: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. METHODS: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. RESULTS: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. CONCLUSIONS: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays."],"journal":"Clin Infect Dis","authors":["Xiang, Fei","Wang, Xiaorong","He, Xinliang","Peng, Zhenghong","Yang, Bohan","Zhang, Jianchu","Zhou, Qiong","Ye, Hong","Ma, Yanling","Li, Hui","Wei, Xiaoshan","Cai, Pengcheng","Ma, Wan-Li"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32306047","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1093/cid/ciaa461","keywords":["covid-19","elisa","sars-cov-2","diagnosis","serological test"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493367091200,"score":328.3702},{"pmid":32251798,"pmcid":"PMC7194885","title":"Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.","text":["Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.","OBJECTIVE: To investigate the diagnostic value of serological testing and dynamic variance of serum antibody in coronavirus disease 2019 (COVID-19). METHODS: This study retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with a suspected infection, in whom the disease was eventually excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis. RESULTS: Compared to molecular detection, the sensitivities of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificities were 100% and 90.9%, respectively.In the COVID-19 group, the IgM-positive rate increased slightly at first and then decreased over time; in contrast, the IgG-positive rate increased to 100% and was higher than IgM at all times. The IgM-positive rate and titer were not significantly different before and after conversion to virus-negative. The IgG-positive rate was up to 90% and not significantly different before and after conversion to virus-negative. However, the median IgG titer after conversion to virus-negative was double that before, and the difference was significant. CONCLUSIONS: Viral serological testing is an effective means of diagnosis for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than those of IgM in COVID-19.","Int J Infect Dis","Jin, Yujiao","Wang, Miaochan","Zuo, Zhongbao","Fan, Chaoming","Ye, Fei","Cai, Zhaobin","Wang, Ying","Cui, Huaizhong","Pan, Kenu","Xu, Aifang","32251798"],"abstract":["OBJECTIVE: To investigate the diagnostic value of serological testing and dynamic variance of serum antibody in coronavirus disease 2019 (COVID-19). METHODS: This study retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with a suspected infection, in whom the disease was eventually excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis. RESULTS: Compared to molecular detection, the sensitivities of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificities were 100% and 90.9%, respectively.In the COVID-19 group, the IgM-positive rate increased slightly at first and then decreased over time; in contrast, the IgG-positive rate increased to 100% and was higher than IgM at all times. The IgM-positive rate and titer were not significantly different before and after conversion to virus-negative. The IgG-positive rate was up to 90% and not significantly different before and after conversion to virus-negative. However, the median IgG titer after conversion to virus-negative was double that before, and the difference was significant. CONCLUSIONS: Viral serological testing is an effective means of diagnosis for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than those of IgM in COVID-19."],"journal":"Int J Infect Dis","authors":["Jin, Yujiao","Wang, Miaochan","Zuo, Zhongbao","Fan, Chaoming","Ye, Fei","Cai, Zhaobin","Wang, Ying","Cui, Huaizhong","Pan, Kenu","Xu, Aifang"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251798","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijid.2020.03.065","keywords":["covid-19","diagnosis","immunoglobulin g","immunoglobulin m","sars-cov-2","serological test"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490956414977,"score":300.49652}]}